Where can I find the specific financial results for Elevance Health's third quarter of 2024?

The specific financial results for the quarter ended September 30, 2024, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. You will need to refer to that document for detailed figures on revenue, earnings, and other financial metrics.

What are the main risks highlighted by Elevance Health in this filing?

Elevance Health highlights a broad range of risks that could affect its future performance. These include trends in healthcare costs and utilization, regulatory changes (especially concerning healthcare and insurance), operational and technological risks (including data security and system failures), competitive pressures, risks associated with government programs like Medicare and Medicaid, and potential impacts from economic conditions and litigation.

Does this 8-K filing provide updated financial guidance for the rest of the year?

This 8-K filing primarily serves to announce the Q3 2024 results and directs investors to the accompanying press release for details. Any updated financial guidance for the remainder of the year would typically be found within that press release or in subsequent investor communications. The 8-K text itself does not contain specific forward-looking guidance.

What is the significance of the disclaimer about information not being 'filed'?

The disclaimer states that the information furnished in Item 2.02 and Exhibit 99.1 is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means the company generally cannot be held liable for misstatements or omissions in that specific furnished information in the same way it could for formally 'filed' information. It also clarifies that this furnished information will not be automatically incorporated by reference into future SEC filings unless explicitly stated.

ELV 8-K: Earnings & Results

Summary

Elevance Health, Inc. (ELV) filed an 8-K on October 17, 2024, primarily to report its financial results for the third quarter ended September 30, 2024. The filing includes a press release (Exhibit 99.1) detailing these results. While the specific financial figures are not presented within the 8-K text itself, this report serves as the official notification to the market of their latest quarterly performance. Investors should refer to the furnished press release for detailed financial metrics, including revenue, earnings, and any forward-looking guidance provided by the company. This report also includes standard forward-looking statements that caution investors about potential risks and uncertainties that could cause actual results to differ from projections. These risks are typical for a health insurer and cover areas such as healthcare costs, regulatory changes, operational and technological challenges, competitive pressures, and government program risks (Medicare/Medicaid). Investors are advised to review these risks carefully, as they provide context for the company's financial performance and future outlook.

Key Highlights

1Elevance Health reported its Q3 2024 financial results via an 8-K filing on October 17, 2024.
2The key financial details are contained in the press release furnished as Exhibit 99.1.
3The filing itself does not provide specific earnings or revenue figures, directing investors to the accompanying press release.
4Standard forward-looking statements are included, warning of risks that could impact future performance.
5Key risk factors mentioned include healthcare cost trends, regulatory impacts, operational/tech challenges, and competition.
6The company also noted potential risks related to government programs like Medicare and Medicaid.
7Investors are urged to read the full press release and consider the disclosed risks when evaluating the company's performance and outlook.

Elevance Health, Inc. 8-K Report, Financial Results (Oct 17, 2024)

Summary

Key Highlights

Frequently Asked Questions